Torii Pharmaceutical Co ROA 2024

ماذا تفعل Torii Pharmaceutical Co؟

Torii Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1921. The company is headquartered in Tokyo and employs over 1,200 employees. Torii specializes in the development and manufacturing of medicines for the treatment of diseases such as diabetes, cancer, kidney and liver diseases, as well as allergic diseases and mental disorders. The business model of Torii is based on developing and manufacturing innovative medicines that have a high benefit for patients. To achieve this, the company invests a large portion of its revenue in research and development of new drugs. The goal is to improve both the quality of life of patients and support society by creating new healing opportunities. Torii is divided into two business segments: Pharma and Nutraceuticals. In the Pharma segment, the company produces prescription drugs that are primarily sold in Japanese hospitals and clinics. On the other hand, the Nutraceutical division offers products that are sold without a prescription and focus on dietary supplements and health-promoting products. Torii has a wide range of products, ranging from various medications to dietary supplements and functional foods. One of Torii's most well-known products is an antidiabetic called "Trelagliptin". The medication is used to treat type 2 diabetes and is the best-selling diabetes medication in Japan. Another important product from Torii is "UFT™", a chemotherapy treatment for cancer. UFT™ is particularly effective in treating stomach, colon, and lung cancer. Another significant medication is "Micardis™", a blood pressure-lowering medication. The medication lowers blood pressure without unwanted side effects and is also available in Europe and the United States. In the Nutraceutical division, Torii offers various products such as vitamins, minerals, dietary supplements, functional foods, and beverages. One highlight is "Real Gold Three", a dietary supplement that contains eight valuable herbs and focuses on improving the immune system. The product is sold in both Japan and China. In recent years, the company has established strategic partnerships with various other companies to promote innovation and accelerate growth. In 2019, the company signed a collaboration agreement with the Vietnamese division of the British pharmaceutical giant GlaxoSmithKline (GSK). The goal of the collaboration is to strengthen the distribution of GSK products in the Vietnamese market. Torii sees itself not only as a pharmaceutical company but also as part of society. The company actively supports social projects and corporate social responsibility (CSR). For example, Torii supports the "Operation Smile" program, which aims to help children with cleft lips and palates. Overall, Torii is an important player in the Japanese pharmaceutical market specializing in research, development, and marketing of innovative medicines. The company has a broad portfolio and has expanded its product range in recent years with various high-quality products. With its partnerships and social initiatives, Torii demonstrates that it is not only a commercial company but also makes an important contribution to society and the health of people. Torii Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.